# Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

> **NCT01766817** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 325 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** BMS-986020
- **DRUG:** Placebo matching with BMS-986020

## Key facts

- **NCT ID:** NCT01766817
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-31
- **Primary completion:** 2016-02-29
- **Final completion:** 2016-02-29
- **Target enrollment:** 325 (ACTUAL)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01766817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01766817, "Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01766817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*